Recent Developments in Novel Antidepressants Targeting α4β2-Nicotinic Acetylcholine Receptors: Miniperspective

DSpace/Manakin Repository

Recent Developments in Novel Antidepressants Targeting α4β2-Nicotinic Acetylcholine Receptors: Miniperspective

Citable link to this page

 

 
Title: Recent Developments in Novel Antidepressants Targeting α4β2-Nicotinic Acetylcholine Receptors: Miniperspective
Author: Yu, Li-Fang; Zhang, Han-Kun; Caldarone, Barbara J.; Eaton, J. Brek; Lukas, Ronald J.; Kozikowski, Alan P.

Note: Order does not necessarily reflect citation order of authors.

Citation: Yu, Li-Fang, Han-Kun Zhang, Barbara J. Caldarone, J. Brek Eaton, Ronald J. Lukas, and Alan P. Kozikowski. 2014. “Recent Developments in Novel Antidepressants Targeting α4β2-Nicotinic Acetylcholine Receptors: Miniperspective.” Journal of Medicinal Chemistry 57 (20): 8204-8223. doi:10.1021/jm401937a. http://dx.doi.org/10.1021/jm401937a.
Full Text & Related Files:
Abstract: Nicotinic acetylcholine receptors (nAChRs) have been investigated for developing drugs that can potentially treat various central nervous system disorders. Considerable evidence supports the hypothesis that modulation of the cholinergic system through activation and/or desensitization/inactivation of nAChR holds promise for the development of new antidepressants. The introductory portion of this Miniperspective discusses the basic pharmacology that underpins the involvement of α4β2-nAChRs in depression, along with the structural features that are essential to ligand recognition by the α4β2-nAChRs. The remainder of this Miniperspective analyzes reported nicotinic ligands in terms of drug design considerations and their potency and selectivity, with a particular focus on compounds exhibiting antidepressant-like effects in preclinical or clinical studies. This Miniperspective aims to provide an in-depth analysis of the potential for using nicotinic ligands in the treatment of depression, which may hold some promise in addressing an unmet clinical need by providing relief from depressive symptoms in refractory patients.
Published Version: doi:10.1021/jm401937a
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4207546/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:17295788
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters